Patients with type 2 diabetes treated for 84 weeks with injected extended-release once-weekly exenatide (Bydureon; Amylin Pharmaceuticals, Lilly, and Alkermes) demonstrated superior ongoing glycemic control, sustained overall weight loss, and a lower risk for hypoglycemia than patients treated with insulin glargine, according to new data from the DURATION-3 trial.